---
Oracle and Bloom Energy: Powering the AI Buildout
The rally in Oracle and Bloom Energy shares continues to underscore one of the most pressing bottlenecks in the AI revolution: power. The two companies announced an expanded partnership in which Bloom Energy will support the rapid buildout of AI infrastructure and cloud computing capacity. Under the deal, Oracle is looking to procure up to 2.8 gigawatts of Bloom fuel cell systems, building on a previously contracted 1.2 gigawatts that is already being deployed through next year.
The logic behind this deal is straightforward. AI data centers consume enormous amounts of electricity, and traditional electric grids are often too slow to expand or already overloaded. Bloom's fuel cells offer on-site electricity generation, faster deployment than waiting on grid upgrades, and reliable backup power — critical attributes for supporting the non-stop workloads that AI demands. Oracle has been aggressively building out its cloud and AI business, and securing dedicated power sources is essential to keeping that expansion on track.
The market reaction has been emphatic. Oracle shares gained nearly 13% the day before the announcement and tacked on another 6–7% the following morning. Bloom Energy surged roughly 14%, hitting a new multi-year high. The partnership signals that the infrastructure demands of AI are far from fully priced in, and companies that can solve the energy constraint stand to benefit enormously.
CarMax: Beating Expectations Isn't Always Enough
CarMax reported earnings that technically beat analyst expectations, yet the stock slumped over 14%. The disconnect illustrates a harsh reality in today's market: beating lowered expectations means little when the underlying fundamentals are deteriorating.
Adjusted earnings per share came in at 34 cents, well above the 21-cent consensus estimate. Revenue landed at $5.95 billion, also topping expectations. But both figures were down on a year-over-year basis, with revenue declining 1%. Investors zeroed in on the weakness beneath the surface. Retail used unit sales fell 0.8%, and comparable store used unit sales declined nearly 2%. Gross profit dropped more than 9%.
CarMax appears to be using lower prices to stimulate demand — a strategy that benefits consumers but punishes margins. On the wholesale side, unit volume rose 3%, a positive sign, but average wholesale prices dropped about $270, pressuring revenue. Gross profit per wholesale unit also fell. The picture is one of more cars moving on both the wholesale and retail sides, but at lower profitability.
The company is in the midst of a leadership transition, with a new CEO who took over in March and has stated that execution and efficiency are top priorities. Adding another layer of complexity, activist investor Starboard Value recently disclosed a stake in the company, suggesting external pressure for change may be mounting. For now, the market's verdict is clear: incremental improvements are not enough to offset the ongoing margin reset.
Johnson & Johnson: Navigating the Patent Cliff
Johnson & Johnson delivered a strong first quarter, topping expectations on both the top and bottom lines. Adjusted earnings per share came in at $2.70, with revenue just above $24 billion. The company also raised its full-year outlook — a confident signal in an uncertain environment.
The strength was driven in large part by the cancer drug Darzalex and the company's psoriasis treatment portfolio. These helped offset a sharp approximately 60% drop in sales of Stelara, which lost patent protection. The so-called patent cliff has been a persistent worry for J&J investors: when a blockbuster drug loses exclusivity, where does growth come from? This quarter provided a reassuring answer, as the rest of the pipeline and the medical technology unit delivered solid growth to compensate.
J&J also raised its quarterly dividend, a move that tends to resonate with the income-focused investor base that gravitates toward large-cap healthcare names. Shares dipped slightly at the open but recovered in real time to trade up half a percent. Year to date, J&J has been a double-digit gainer, outperforming the S&P 500 — consistent with the broader analyst thesis that healthcare would be an outperforming sector this year.
The Bigger Picture
These three stories capture distinct themes in the current market. Oracle and Bloom Energy reflect the insatiable demand for AI infrastructure and the creative solutions required to power it. CarMax highlights the challenges facing consumer-facing businesses navigating soft demand and margin compression in a price-sensitive environment. And Johnson & Johnson demonstrates the resilience of a well-diversified healthcare giant managing through a major patent transition. Together, they paint a picture of a market that continues to reward innovation and punish stagnation, regardless of whether headline numbers beat or miss.